Moreno C, Byrd JC, Hillmen P, et al. Ibrutinib in previously treated chronic lymphocytic leukemia updated efficacy and safety of the RESONATE study with up to four years of follow-up. EHA 2017, abstract S769.
Khorana-score ook geschikt voor ambulante kankerpatiënten
jan 2019 | Benigne hematologie